Please wait...


Generic Name: pegvaliase (peg VAL i ase)
Brand Name: Palynziq
Physician reviewed Palynziq patient information - includes Palynziq description, dosage and directions.
  • Prescription Settings

Prices and coupons of Palynziq

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code

Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Palynziq is a man-made form of an enzyme that metabolizes phenylalanine. Palynziq is used in adults with phenylketonuria (PKU) to lower phenylalanine blood levels when they are not controlled with other treatment Palynziq is available only from a certified pharmacy under a special program. Palynziq may also be used for purposes not listed in this medication guide. Palynziq can cause a serious allergic reaction. You will receive your first dose in a hospital or clinic setting to make sure you do not have an allergic reaction. Learn more

Palynziq Side Effects

Palynziq Side Effects

Note: This document contains side effect information about pegvaliase. Some of the dosage forms listed on this page may not apply to the brand name Palynziq.

For the Consumer

Applies to pegvaliase: subcutaneous solution


Subcutaneous route (Solution)

Anaphylaxis has been reported after administration of pegvaliase-pqpz and may occur at any time during treatment. Administer the initial dose of pegvaliase-pqpz under the supervision of a healthcare provider equipped to manage anaphylaxis, and closely observe patients for at least 60 minutes following injection. Prior to self-injection, confirm patient competency with self-administration, and patient’s and observer’s ability to recognize signs and symptoms of anaphylaxis and to administer auto-injectable epinephrine, if needed. Prescribe auto-injectable epinephrine. Prior to first dose, instruct the patient and observer (if applicable) on its appropriate use. Instruct the patient to seek immediate medical care upon its use. Instruct patients to carry auto-injectable epinephrine with them at all times during pegvaliase-pqpz treatment. Pegvaliase-pqpz is available only through a restricted program called the Palynziq(TM) REMS.

Along with its needed effects, pegvaliase (the active ingredient contained in Palynziq) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking pegvaliase:

More common

  • Diarrhea
  • fever
  • joint or muscle pain
  • large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or genitals
  • nausea
  • numbness or tingling of the face, hands, or feet
  • redness and soreness of the eyes
  • skin rash
  • sores in the mouth
  • stomach pain
  • swelling of the feet or lower legs
  • vomiting


  • Feeling of discomfort
  • itching
  • joint swelling
  • swollen lymph glands

Some side effects of pegvaliase may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

  • Anxiety
  • bleeding, blistering, burning, coldness, discoloration of skin, feeling of pressure, hives, infection, inflammation, itching, lumps, numbness, pain, rash, redness, scarring, soreness, stinging, swelling, tenderness, tingling, ulceration, or warmth at the injection site
  • cough
  • difficulty in moving
  • dizziness
  • headache
  • loss or thinning of hair
  • muscle stiffness
  • pain in the mouth and throat
  • stuffy nose
  • unusual tiredness or weakness

For Healthcare Professionals

Applies to pegvaliase: subcutaneous solution


The most commonly reported adverse reactions have included injection site reactions, arthralgia, hypersensitivity reactions, headache, generalized skin reactions lasting at least 14 days, pruritus, nausea, abdominal pain, oropharyngeal pain, vomiting, cough, diarrhea, and fatigue.


Very common (10% or more): Hypersensitivity reactions (up to 69%)

Common (1% to 10%): Anaphylaxis

During clinical trials, a total of 37 anaphylactic episodes were reported in 26 patients (n=285). The rate of anaphylaxis was highest during induction and titration phase. Signs and symptoms of anaphylaxis included syncope, hypotension, hypoxia, dyspnea, wheezing, chest discomfort/chest tightness, tachycardia, angioedema (swelling of face, lips, eyes, tongue), throat tightness, skin flushing, rash, urticaria, pruritus, and gastrointestinal symptoms (vomiting, nausea, diarrhea). Anaphylaxis occurred within 1 hour in 84% (28/37) of the reported anaphylaxis episodes. One additional case occurred within the first year of dosing (78%; 29/37 episodes), and the remaining cases occurred after one year of dosing and up to 834 days (2.3 years) into treatment.

Hypersensitivity reactions other than anaphylaxis have been reported in 69% of patients (196/285). Hypersensitivity reactions have included rash, urticaria, anaphylaxis, rash generalized, hypersensitivity, rash erythematous, rash maculo-papular, rash pruritic, serum sickness, swelling face, dermatitis contact, swollen tongue, lip swelling, rash macular, pharyngeal edema, injection site hypersensitivity, eczema, drug eruption, dermatitis allergic, dermatitis, tongue edema, palatal edema, edema mouth, multiple allergies, lip edema, eye edema, exfoliative rash, drug hypersensitivity, dermatitis atopic, dermatitis acneiform, pruritus allergic, mouth swelling, implant site rash, gingival swelling, face edema, eyelid edema, eye swelling, dermatitis psoriasiform, dermatitis infected, conjunctivitis allergic, bronchospasm, angioedema, allergic sinusitis, and allergic cough.


Injection site reactions have included: Erythema, pruritus, pain, bruising, rash, swelling, urticaria, induration, hemorrhage, edema, mass, inflammation, nodule, discoloration, warmth, hematoma, irritation, vesicles, hypersensitivity, papule, discomfort, scar, paresthesia, hypertrophy, extravasation, and dryness

Very common (10% or more): Injection site reactions (up to 88%)


Generalized skin reactions include pruritus, rash, urticaria, dry skin, rash erythematous, erythema, cellulitis, rash macular, pruritus generalized, petechiae, dermatitis allergic, skin infection, skin induration, rash maculo-papular, rash generalized, pharyngeal edema, macule, granulomatous dermatitis, exfoliative rash, drug eruption, dermatitis atopic, dermatitis, xanthogranuloma, skin plaque, skin mass, skin lesion, skin hypopigmentation, skin hypertrophy, skin hyperpigmentation, skin exfoliation, septal panniculitis, scleroderma, scar, rash pruritic, rash papular, psoriatic arthropathy, pruritus allergic, papule, necrobiosis lipoidica diabeticorum, furuncle, eczema, ecchymosis, dermatitis psoriasiform, dermatitis infected, and blister.

Very common (10% or more): Generalized skin reaction lasting at least 14 days (up to 37%), pruritus (up to 24%), alopecia (up to 17%)


Very common (10% or more): Nausea (up to 26%), abdominal pain (up to 25%), oropharyngeal pain (up to 23%), vomiting (up to 26%), diarrhea (up to 22%)


Arthralgia includes: Pain in extremity, back pain, musculoskeletal pain, and neck pain.

Very common (10% or more): Arthralgia (up to 74%)


Very common (10% or more): Anxiety (up to 18%)


Very common (10% or more): Cough (up to 22%), nasal congestion (up to 18%)


Very common (10% or more): Fatigue (up to 22%)

Nervous system

Very common (10% or more): Headache (up to 50%)

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Palynziq